A summary of the publications members of the DaC-VaP-2 team have written or significantly contributed to. Whilst our research is now complete, several publications are either in press or works in progress.
Each of studies below contribute to one of the project's four research streams. These streams investigate the uptake, safety and effectiveness of COVID-19 vaccines either in different groups or under different circumstances.
The four research streams are:
- [in] pregnancy
- [in] children and young people (CYP)
- [when given as] booster [doses]
- [on disease caused by different] variants [of the SARS-CoV-2 virus]
COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales
January 2023: A new research study published in the journal, Vaccine, has uncovered rates of COVID-19 booster vaccination uptake and subsequent infection breakthrough amongst healthcare workers in Wales. This study is part of DaC-VaP-2's vaccine boosters research stream.
Confirmed SARS-CoV-2 infection in Scottish neonates 2020-2022
January 2023: Research published in Archives of Disease in Childhood looks at the number of newborn babies in Scotland with SARS-CoV-2 viral infection. This study is part of DaC-VaP-2's pregnancy research stream.
Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations across the UK
October 2022: Study finds that protection provided by first and second doses of Oxford-AstraZeneca ChAdOx1, as well as first dose of Pfizer BioNTech BNT162b2 vaccines completely wanes by 80 days post-vaccination. This study is part of DaC-VaP-2's waning research stream.
Early Pregnancy Outcomes following COVID-19 Vaccination and SARS-COV-2 Infection in Pregnant Women
October 2022: Research published in Nature Communications looks at potential links between COVID-19 vaccines, SARS-CoV-2 infections, and miscarriage or ectopic pregnancy. This study is part of DaC-Vap-2's pregnancy research stream.
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters
October 2022: Research published in The Lancet looks at who is at higher risk of serious illness following an Omicron infection, after a third or booster dose of COVID-19 vaccine. This study is part of DaC-VaP-2's boosters work stream.
Pregnancy outcomes following Delta and Omicron SARS-CoV-2 infection in Scotland
October 2022: Research published in The Lancet Respiratory Medicine looks at the impact of COVID-19 on the health of pregnant women, and their babies, after Delta and Omicron infections in Scotland. This study is part of DaC-VaP-2's pregnancy research stream.
BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
September 2022: Research published in The Lancet Regional Health Europe looks at the uptake, safety, and effectiveness over time of the Pfizer-BioNTech COVID-19 vaccine for people aged 12-17 in Scotland. This study is part of DaC-VaP-2's Children and Young People research stream.
Evaluation of Risk Factors for Postbooster Omicron COVID-19 Deaths in England
September 2022: Study investigating risk factors associated with COVID-19 deaths after a person received their primary and booster dose vaccine. identify risk factors associated
COVID-19 hospital admissions by vaccination and pregnancy status, England: 8 December 2020 to 31 August 2021
July 2022: Estimates of coronavirus (COVID-19) hospital admission rates in England by vaccination status in pregnant and non-pregnant women, published by the Office of National Statistics. This study is part of DaC-VaP-2's pregnancy work stream.
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland
April 2022: Research published in The Lancet Infectious Diseases looks at COVID-19 hospital admissions, and the effectiveness of vaccine boosters, in people infected by the Omicron variant in Scotland. This study is part of DaC-VaP-2's variants research stream.
Waning of Pfizer or Oxford-AstraZeneca Boosters against symptomatic infection and severe COVID-19 in Brazil and Scotland (pre-print)
April 2022: Pre-print article published on preprints with The Lancet investigates the waning effectiveness of booster vaccines from Pfizer BioNTech (BNT162b2) and Oxfrord-AstraZeneca (ChadOx1), against symptomatic infection and severe COVID-19 in Brazil and Scotland. This study is part of DaC-VaP-2's waning research stream.
BNT162b2 and ChAdOx1 nCoV-19 Vaccinations, Incidence of SARS-CoV-2 Infections and COVID-19 Hospitalisations in Scotland in the Delta era
March 2022: Research published in the Journal of Global Health looks at patterns of COVID-19 disease and hospital admissions in Scotland when the Delta variant was most common. This study is part of DaC-VaP-2's variants work stream.
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland
January 2022: Research published in Nature Medicine looks at COVID-19 disease and vaccination in pregnant women in Scotland, and the impact this has had on their health. This study is part of DaC-VaP-2's pregnancy work stream.
(pre-print) Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease
December 2021: Unpublished pre-print study looking at the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Omicron variant of concern.
Children and Young People - A complex discussion on vaccination (part 2)
December 2021: As part of their work, our researchers have written two editorial articles discussing the COVID-19 pandemic in children and young people. This article is the second of two articles that were published and is part of DaC-VaP-2's Children and Young People research stream.
Children and Young People - COVID-19 pandemic between 2020-2021 (part 1)
December 2021: As part of their work, our researchers have written two editorial articles discussing the COVID-19 pandemic in children and young people. This article is one of two that were published and is part of DaC-VaP-2's Children and Young People research stream.
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time in Brazil and Scotland
December 2021: The protection offered by the Oxford-Astra Zeneca Covid-19 vaccine declines after three months of receiving two doses, a study says. This study is part of DaC-VaP-2's variants work stream.
To find out more about our previous work on the original DaC-VaP project;
Visit the DaC-VaP research site